Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

RSS icon
Samin Sharma, MD, director of interventional cardiology and director of clinical cardiology, Mount Sinai Hospital, New York, discusses the first-in-human use of the Magenta Elevate percutaneous left ventricular assist device (pLVAD) with a small 10 French size and 5.5 liters per minute of hemodynamic support.

Initial results promising for world's smallest percutaneous heart pump

A new 10 French percutaneous heart pump could help greatly reduce vascular complications and improve cardiogenic shock outcomes.

Video of Yousif Ahmad, MD, Yale, discussing IVL advances and increased reinbursements

Tracking key advances in intravascular lithotripsy

Yousif Ahmad, MD, spoke with Cardiovascular Business about the latest advances in IVL therapy, including new reimbursement changes for the technology. 

Ziad Ali, MD, explaines the impact of coronary intravascular lithotripsy (IVL) use in nodular and eccentric calcium morphologies at TCT 2023. IVL was found to produce better outcomes than atherectomy or high pressure balloons. #TCT #TCT2023 #TCT23 #IVL

IVL is safe and effective across all calcium morphologies, new research confirms

Ziad Ali, MD, detailed two studies he presented on coronary intravascular lithotripsy at TCT 2023 in San Francisco.

Ramon Varcoe explains the LIFE-BTK trial for the Abbott Esprit fully bioresobable scaffold at TCT23.

Fully bioresorbable stents boost care for CLI patients in LIFE-BTK trial

Ramon Varcoe, MBBS, co-principal investigator for the LIFE-BTK trial, discussed the results with Cardiovascular Business at TCT 2023. "I can't wait to start using these in my patients. It's going to make a huge difference."

Firas Zahr, MD,director of interventional cardiology, co-director, complex heart valve program, Oregon Health and Science University, discusses the one-year outcomes for transferral transcatheter mitral valve replacement (TMVR) in the Medtronic Intrepid Early Feasibility Study presented at TCT 2023.

Intrepid transfemoral transcatheter mitral valve shows favorable results after 1 year

Firas Zahr, MD, spoke to Cardiovascular Business about early data on the Medtronic TMVR device. His team's study is designed to follow patients for a total of five years.

PHOTO GALLERY: Interventional cardiology technologies at TCT 2023

Browse through some of the many highlights from TCT 2023 in San Francisco.

Matthias Götberg discusses iFR vs. FFR from the National SWEDEHEART Quality Registry at #TCT2023. #iFR

iFR and FFR are equal, new long-term analysis confirms

There were some concerns among researchers after one study suggested iFR may increase the risk of mortality. New data presented at TCT 2023, however, showed that the two technologies are linked to similar outcomes. 

Video of Kendra Grubb discussing transcatheter tricuspid and mitral advancements at TCT 2023.

Key trends in transcatheter tricuspid and mitral valve technologies

The mitral valve has been an especially challenging target for transcatheter interventions, but there are reasons to think key breakthroughs are on the horizon. We talked to Kendra Grubb, MD, about this and other ongoing trends at TCT 2023. 

Displaying 41 - 48 of 138

Around the web

Health Imaging
Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business
U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.